[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI (TEM) may be building one of healthcare's fastest-growing artificial intelligence (AI) platforms, but the stock hasn’t given investors much to celebrate lately. Shares are down roughly 15% over the past year and about 4% year-to-date (YTD), even as the company continues to report strong revenue growth and expand its footprint in AI-powered precision medicine. TEM stock even has an approximately 4% weightage in Cathie Wood’s ARK Invest ETFs (ARKG) (ARKK). With the stock pulling back while the fundamentals continue improving, investors are left with a critical choice. 

Does this pullback represent a buying opportunity or a warning sign?

Fundamentals

See More
  • Market Capitalization, $K 158,771,968
  • Shares Outstanding, K 1,241,570
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,370 M
  • EBITDA $ 13,130 M
  • 60-Month Beta 0.31
  • Price/Sales 5.39
  • Price/Cash Flow 12.21
  • Price/Book 6.77

Options Overview Details

View History
  • Implied Volatility 29.03% (+0.37%)
  • Historical Volatility 26.64%
  • IV Percentile 46%
  • IV Rank 40.30%
  • IV High 40.29% on 10/13/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 3) 2.54 (2.01%)
  • Put/Call Vol Ratio 0.45
  • Today's Volume 5,108
  • Volume Avg (30-Day) 9,016
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 166,131
  • Open Int (30-Day) 171,399
  • Expected Range 123.79 to 128.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-7.20
  • Number of Estimates 6
  • High Estimate $-6.99
  • Low Estimate $-7.50
  • Prior Year $2.01
  • Growth Rate Est. (year over year) -458.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
121.39 +4.07%
on 06/10/26
133.99 -5.72%
on 06/01/26
-8.10 (-6.03%)
since 05/29/26
3-Month
121.39 +4.07%
on 06/10/26
142.97 -11.64%
on 04/09/26
-7.92 (-5.90%)
since 03/27/26
52-Week
107.75 +17.24%
on 07/21/25
157.29 -19.68%
on 02/11/26
+15.66 (+14.15%)
since 06/27/25

Most Recent Stories

More News
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 42.36 (+2.24%)
AZN : 190.95 (+1.35%)
MRK : 129.38 (+0.56%)
GILD : 126.33 (-1.21%)
TEM : 58.31 (+3.87%)
GSK : 52.81 (+0.59%)
ARKK : 80.63 (+3.20%)
BMY : 58.56 (+1.81%)
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

– Trodelvy is a New Backbone Therapy and the Only Approved ADC in First-Line mTNBC Across PD-L1 Status – –...

GILD : 126.33 (-1.21%)
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

IBB : 189.79 (+1.30%)
VRTX : 499.65 (+1.69%)
GILD : 126.33 (-1.21%)
AMGN : 360.55 (+0.62%)
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

–Trodelvy is the First Antibody-Drug Conjugate (ADC) and First New Treatment Option in 20 Years in Europe for Certain Patients with First-Line Metastatic Triple-Negative Breast Cancer – ...

GILD : 126.33 (-1.21%)
3 S&P 500 Stocks with Exciting Potential

3 S&P 500 Stocks with Exciting Potential

NVDA : 194.97 (+1.27%)
AMP : 446.79 (-1.33%)
GILD : 126.33 (-1.21%)
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?

GILD : 126.33 (-1.21%)
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off

1 Cash-Producing Stock Worth Investigating and 2 We Brush Off

SEDG : 55.36 (+6.98%)
HRB : 38.22 (+2.69%)
GILD : 126.33 (-1.21%)
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

– Submission Supported By Clinical Profile of Lenacapavir, Which Demonstrated High Efficacy in HIV Prevention Across Two Clinical Trials –

GILD : 126.33 (-1.21%)
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

Gilead Sciences today announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts to the current outbreak of Ebola...

GILD : 126.33 (-1.21%)
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

- Three-year, ~$3M commitment to expand leadership development, strengthen HIV education and engagement, and preserve the HIV movement’s history for future generations -

GILD : 126.33 (-1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 131.67
2nd Resistance Point 130.26
1st Resistance Point 128.30
Last Price 126.33
1st Support Level 124.93
2nd Support Level 123.52
3rd Support Level 121.56

See More

52-Week High 157.29
Fibonacci 61.8% 138.37
Fibonacci 50% 132.52
Fibonacci 38.2% 126.67
Last Price 126.33
52-Week Low 107.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.